N-(2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)quinoline-8-sulfonamide | 215511-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: N-(2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)quinoline-8-sulfonamide
• CAS: 215511-35-6
• 化学式: C₂₄H₁₈N₄O₃S
• 分子量: 442.498
• InChiKey: TXBWAWDCFHUYIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)quinoline-8-sulfonamide 在 sodium hydroxide 、 sodium hydride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.0h， 生成 2-[2-oxo-5-phenyl-3-(quinolin-8-ylsulfonylamino)-3H-1,4-benzodiazepin-1-yl]acetic acid
  参考文献：
  名称：

  Design, syntheses, and activity of new 3-[(sulfonylaryl)-amino]-1,4-benzodiazepin-2-one derivatives as α-thrombin inhibitors

  摘要：

  Thrombin plays a central role in thrombosis. Because of the medical need for novel antithrombotic drugs, a search for structurally novel thrombin inhibitors was undertaken. In the absence of a crystal structure, a class was designed based on a modeling approach which involved placing the essential functional groups of the thrombin antagonist MD-805 [1] (Argatroban) into the benzodiazepine nucleus. The best superposition was obtained with a 1,4-benzodiazepin-2-one containing a 1,2,3,4-tetrahydro quinolylsulfonyl moiety in the 3-position, a guanidino-phenyl at the 5-position, and Ni-substituted with an acetic acid. Synthesis of these molecules provided compounds with an inhibitory activity with K-i in the range of 40-1000 mu M. A report on the crystal structure of thrombin*hirudin(55-65)*MD-805 complex [2] suggested subsequent molecular modeling investigations to rationalize the pharmacological results. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(98)80048-2
• 作为产物：
  描述：

  喹啉-8-磺酰氯 、 3-氨基-5-苯基-1,3-二氢-2H-1,4-苯并二氮杂革-2-酮 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 0.5h， 以80%的产率得到N-(2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)quinoline-8-sulfonamide
  参考文献：
  名称：

  Design, syntheses, and activity of new 3-[(sulfonylaryl)-amino]-1,4-benzodiazepin-2-one derivatives as α-thrombin inhibitors

  摘要：

  Thrombin plays a central role in thrombosis. Because of the medical need for novel antithrombotic drugs, a search for structurally novel thrombin inhibitors was undertaken. In the absence of a crystal structure, a class was designed based on a modeling approach which involved placing the essential functional groups of the thrombin antagonist MD-805 [1] (Argatroban) into the benzodiazepine nucleus. The best superposition was obtained with a 1,4-benzodiazepin-2-one containing a 1,2,3,4-tetrahydro quinolylsulfonyl moiety in the 3-position, a guanidino-phenyl at the 5-position, and Ni-substituted with an acetic acid. Synthesis of these molecules provided compounds with an inhibitory activity with K-i in the range of 40-1000 mu M. A report on the crystal structure of thrombin*hirudin(55-65)*MD-805 complex [2] suggested subsequent molecular modeling investigations to rationalize the pharmacological results. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(98)80048-2

文献信息

• Design, syntheses, and activity of new 3-[(sulfonylaryl)-amino]-1,4-benzodiazepin-2-one derivatives as α-thrombin inhibitors
  作者：Daniel Dumas、Gérard Leclerc、John J. Baldwin、S. Dale Lewis、Mark Murcko、Adel M. Naylor-Olsen

  DOI：10.1016/s0223-5234(98)80048-2

  日期：1998.6

  Thrombin plays a central role in thrombosis. Because of the medical need for novel antithrombotic drugs, a search for structurally novel thrombin inhibitors was undertaken. In the absence of a crystal structure, a class was designed based on a modeling approach which involved placing the essential functional groups of the thrombin antagonist MD-805 [1] (Argatroban) into the benzodiazepine nucleus. The best superposition was obtained with a 1,4-benzodiazepin-2-one containing a 1,2,3,4-tetrahydro quinolylsulfonyl moiety in the 3-position, a guanidino-phenyl at the 5-position, and Ni-substituted with an acetic acid. Synthesis of these molecules provided compounds with an inhibitory activity with K-i in the range of 40-1000 mu M. A report on the crystal structure of thrombin*hirudin(55-65)*MD-805 complex [2] suggested subsequent molecular modeling investigations to rationalize the pharmacological results. (C) Elsevier, Paris.